Patents by Inventor Michael A. Marletta
Michael A. Marletta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10202428Abstract: H—NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H—NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H—NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H—NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: GrantFiled: October 12, 2016Date of Patent: February 12, 2019Assignee: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Emily Weinert, Jonathan A. Winger, Michael A. Marletta
-
Publication number: 20170267732Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: ApplicationFiled: October 12, 2016Publication date: September 21, 2017Inventors: Stephen P. L. CARY, Elizabeth M. BOON, Emily WEINERT, Jonathan A. WINGER, Michael A. MARLETTA
-
Patent number: 9493527Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.Type: GrantFiled: September 18, 2014Date of Patent: November 15, 2016Assignee: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Jonathan A. Winger, Michael A. Marletta
-
Patent number: 9493526Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: GrantFiled: September 17, 2014Date of Patent: November 15, 2016Assignee: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Emily Weinert, Jonathan A. Winger, Michael A. Marletta
-
Publication number: 20160168609Abstract: The present disclosure provides compositions and methods related to the degradation of cellulose and cellulose-containing materials. CDH-heme domain polypeptides and GH61 polypeptides and related polynucleotides and compositions are provided herein.Type: ApplicationFiled: November 13, 2015Publication date: June 16, 2016Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Michael A. MARLETTA, James H. DOUDNA CATE, William T. BEESON, IV, Christopher M. PHILLIPS
-
Publication number: 20150376250Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: ApplicationFiled: September 17, 2014Publication date: December 31, 2015Inventors: Stephen P. L. CARY, Elizabeth M. BOON, Emily WEINERT, Jonathan A. WINGER, Michael A. MARLETTA
-
Publication number: 20150266931Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.Type: ApplicationFiled: September 18, 2014Publication date: September 24, 2015Inventors: STEPHEN P. L. CARY, ELIZABETH M. BOON, JONATHAN A. WINGER, MICHAEL A. MARLETTA
-
Patent number: 9125931Abstract: In vitro SELEX has been used to discover high affinity RNA aptamers interacting with the tetracycline repressor protein in a tetracycline-dependent manner. Using in silico RNA folding predictions to guide the design of both aptamer truncations and mutants, minimized tetracycline repressor protein high affinity binding aptamers have been defined. Using one such aptamer, inducible post-transcriptional regulation in vivo has been demonstrated that is predicated on a direct interaction between a tetracycline repressor protein and a RNA aptamer element. These aptamer components can be integrated in any organism to inducibly regulate RNA translation of a gene of interest.Type: GrantFiled: April 6, 2010Date of Patent: September 8, 2015Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Brian J. Belmont, Stephen J. Goldfless, Michael A. Marletta, Jacquin C. Niles
-
Patent number: 8969052Abstract: The present disclosure relates to hydrolysis of hexose-?-lactones by use of an S. thermophile extracellular aldonolactonase. In particular the present disclosure relates to compositions including a S. thermophile extracellular aldonolactonase and methods of use thereof.Type: GrantFiled: March 7, 2014Date of Patent: March 3, 2015Assignee: The Regents of the University of CaliforniaInventors: William T. Beeson, IV, James H. Doudna Cate, Michael A. Marletta
-
Publication number: 20140193870Abstract: The present disclosure relates to hydrolysis of hexose-?-lactones by use of an S. thermophile extracellular aldonolactonase. In particular the present disclosure relates to compositions including a S. thermophile extracellular aldonolactonase and methods of use thereof.Type: ApplicationFiled: March 7, 2014Publication date: July 10, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: William T. BEESON, IV, James H. DOUDNA CATE, Michael A. MARLETTA
-
Patent number: 8703452Abstract: The present disclosure relates to hydrolysis of hexose-?-lactones by use of an S. thermophile extracellular aldonolactonase. In particular the present disclosure relates to compositions including a S. thermophile extracellular aldonolactonase and methods of use thereof.Type: GrantFiled: October 10, 2013Date of Patent: April 22, 2014Assignee: The Regents of the University of CaliforniaInventors: William T. Beeson, IV, James H. Dounda Cate, Michael A. Marletta
-
Publication number: 20140073012Abstract: The present disclosure provides compositions and methods related to the degradation of cellulose and cellulose-containing materials. CDH-heme domain polypeptides and GH61 polypeptides and related polynucleotides and compositions are provided herein.Type: ApplicationFiled: April 4, 2012Publication date: March 13, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Michael A. Marletta, James H. Doudna Cate, William T. Beeson, IV, Christopher M. Phillips
-
Publication number: 20140038245Abstract: The present disclosure relates to hydrolysis of hexose-?-lactones by use of an S. thermophile extracellular aldonolactonase. In particular the present disclosure relates to compositions including a S. thermophile extracellular aldonolactonase and methods of use thereof.Type: ApplicationFiled: October 10, 2013Publication date: February 6, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: William T. BEESON, IV, James H. DOUDNA CATE, Michael A. MARLETTA
-
Publication number: 20130289252Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.Type: ApplicationFiled: February 20, 2013Publication date: October 31, 2013Inventors: Stephen P. L. CARY, Elizabeth M. BOON, Jonathan A. WINGER, Michael A. MARLETTA
-
Patent number: 8569022Abstract: The present disclosure relates to hydrolysis of hexose-?-lactones by use of an S. thermophile extracellular aldonolactonase. In particular the present disclosure relates to compositions including a S. thermophile extracellular aldonolactonase and methods of use thereof.Type: GrantFiled: June 23, 2011Date of Patent: October 29, 2013Assignee: The Regents of the University of CaliforniaInventors: William T. Beeson, IV, James H. Doudna Cate, Michael A. Marletta
-
Publication number: 20130196396Abstract: The present disclosure relates to hydrolysis of hexose-?-lactones by use of an S. thermophile extracellular aldonolactonase. In particular the present disclosure relates to compositions including a S. thermophile extracellular aldonolactonase and methods of use thereof.Type: ApplicationFiled: June 23, 2011Publication date: August 1, 2013Applicant: The Regents of the University of CaliforniaInventors: William T. Beeson, IV, James H. Doudna Cate, Michael A. Marletta
-
Patent number: 8404631Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: GrantFiled: May 21, 2007Date of Patent: March 26, 2013Assignee: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Emily Weinert, Jonathan A. Winger, Michael A. Marletta
-
Patent number: 8404632Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.Type: GrantFiled: May 21, 2007Date of Patent: March 26, 2013Assignee: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Jonathan A. Winger, Michael A. Marletta
-
Publication number: 20110243849Abstract: The present disclosure provides photoactive polypeptides. A subject photoactive polypeptide is useful in a variety of applications, which are also provided.Type: ApplicationFiled: March 31, 2011Publication date: October 6, 2011Inventors: Michael A. Marletta, Michael B. Winter, Emily J. McLaurin, Steven Y. Reece, Charles Olea, JR., Daniel G. Nocera
-
Publication number: 20110245326Abstract: In vitro SELEX has been used to discover high affinity RNA aptamers interacting with the tetracycline repressor protein in a tetracycline-dependent manner. Using in silico RNA folding predictions to guide the design of both aptamer truncations and mutants, minimized tetracycline repressor protein high affinity binding aptamers have been defined. Using one such aptamer, inducible post-transcriptional regulation in vivo has been demonstrated that is predicated on a direct interaction between a tetracycline repressor protein and a RNA aptamer element. These aptamer components can be integrated in any organism to inducibly regulate RNA translation of a gene of interest.Type: ApplicationFiled: April 6, 2010Publication date: October 6, 2011Inventors: Brian J. Belmont, Stephen J. Goldfless, Michael A. Marletta, Jacquin C. Niles